Income Statement Bruker Corporation
Equities
BRKR
US1167941087
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.73 USD | +1.16% | -0.95% | -11.91% |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 2.07B | 1.98B | 2.41B | 2.52B | 2.95B | |||||
Other Revenues, Total | 5.5M | 6M | 7.4M | 6.2M | 13.1M | |||||
Total Revenues | 2.07B | 1.99B | 2.42B | 2.53B | 2.96B | |||||
Cost of Goods Sold, Total | 1.07B | 1.04B | 1.2B | 1.22B | 1.45B | |||||
Gross Profit | 1B | 944M | 1.21B | 1.31B | 1.52B | |||||
Selling General & Admin Expenses, Total | 503M | 472M | 563M | 608M | 730M | |||||
Stock-Based Compensation (IS) | - | - | 2.7M | - | - | |||||
R&D Expenses | 188M | 198M | 221M | 236M | 295M | |||||
Other Operating Expenses | 5.8M | 8.4M | 1.2M | 6.2M | 10.9M | |||||
Other Operating Expenses, Total | 696M | 678M | 788M | 850M | 1.04B | |||||
Operating Income | 304M | 266M | 426M | 456M | 484M | |||||
Interest Expense, Total | -16M | -14.4M | -14.3M | -16.1M | -16.4M | |||||
Interest And Investment Income | 1.3M | 3.2M | 900K | 4.1M | 7.5M | |||||
Net Interest Expenses | -14.7M | -11.2M | -13.4M | -12M | -8.9M | |||||
Income (Loss) On Equity Invest. | - | - | - | 1M | 2M | |||||
Currency Exchange Gains (Loss) | -3.3M | -8M | -4.1M | -5.8M | -13.3M | |||||
Other Non Operating Income (Expenses) | - | - | - | - | -3.1M | |||||
EBT, Excl. Unusual Items | 286M | 247M | 409M | 440M | 461M | |||||
Restructuring Charges | -1.4M | -15.8M | -8.2M | -4.8M | -25.5M | |||||
Merger & Related Restructuring Charges | -4.6M | -3.2M | -6.8M | -19.7M | -11.7M | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | -11.4M | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||
Asset Writedown | - | -2.1M | 500K | -300K | -2.5M | |||||
Insurance Settlements | - | - | - | - | - | |||||
Legal Settlements | - | - | - | - | - | |||||
Other Unusual Items | - | - | -500K | - | 136M | |||||
EBT, Incl. Unusual Items | 280M | 226M | 394M | 415M | 546M | |||||
Income Tax Expense | 82.4M | 64.4M | 113M | 116M | 118M | |||||
Earnings From Continuing Operations | 198M | 161M | 281M | 298M | 428M | |||||
Net Income to Company | 198M | 161M | 281M | 298M | 428M | |||||
Minority Interest | -800K | -3.6M | -3.5M | -1.9M | -1.3M | |||||
Net Income - (IS) | 197M | 158M | 277M | 297M | 427M | |||||
Net Income to Common Incl Extra Items | 197M | 158M | 277M | 297M | 427M | |||||
Net Income to Common Excl. Extra Items | 197M | 158M | 277M | 297M | 427M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 1.27 | 1.03 | 1.83 | 2 | 2.92 | |||||
Basic EPS - Continuing Operations | 1.27 | 1.03 | 1.83 | 2 | 2.92 | |||||
Basic Weighted Average Shares Outstanding | 155M | 153M | 151M | 149M | 146M | |||||
Net EPS - Diluted | 1.26 | 1.02 | 1.81 | 1.99 | 2.9 | |||||
Diluted EPS - Continuing Operations | 1.26 | 1.02 | 1.81 | 1.99 | 2.9 | |||||
Diluted Weighted Average Shares Outstanding | 157M | 155M | 153M | 149M | 147M | |||||
Normalized Basic EPS | 1.15 | 0.98 | 1.66 | 1.84 | 1.96 | |||||
Normalized Diluted EPS | 1.14 | 0.97 | 1.65 | 1.83 | 1.95 | |||||
Dividend Per Share | 0.16 | 0.16 | 0.16 | 0.2 | 0.2 | |||||
Payout Ratio | 12.68 | 15.59 | 8.73 | 10.05 | 6.88 | |||||
Supplemental Items | ||||||||||
EBITDA | 380M | 346M | 515M | 545M | 599M | |||||
EBITA | 343M | 302M | 464M | 494M | 531M | |||||
EBIT | 304M | 266M | 426M | 456M | 484M | |||||
EBITDAR | 409M | 375M | 544M | 570M | 639M | |||||
Total Revenues (As Reported) | 2.07B | 1.99B | 2.42B | 2.53B | 2.96B | |||||
Effective Tax Rate - (Ratio) | 29.39 | 28.52 | 28.71 | 28.05 | 21.55 | |||||
Current Domestic Taxes | 2.8M | -1M | 2.2M | -7.9M | 4.7M | |||||
Current Foreign Taxes | 82.1M | 85.4M | 118M | 135M | 139M | |||||
Total Current Taxes | 84.9M | 84.4M | 120M | 127M | 143M | |||||
Deferred Domestic Taxes | -1.9M | -5.9M | -10.3M | -4.8M | -22.9M | |||||
Deferred Foreign Taxes | -600K | -14.1M | 3.1M | -6.2M | -2.8M | |||||
Total Deferred Taxes | -2.5M | -20M | -7.2M | -11M | -25.7M | |||||
Normalized Net Income | 178M | 151M | 252M | 273M | 287M | |||||
Interest on Long-Term Debt | 16M | 14.4M | 14.3M | 16.1M | 16.4M | |||||
Non-Cash Pension Expense | 2.6M | 3.3M | 2.3M | 1M | 100K | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 15.4M | 9.7M | 13.8M | 19.3M | 23.7M | |||||
Research And Development Expense From Footnotes | 189M | 198M | 221M | 236M | 295M | |||||
Net Rental Expense, Total | 29.4M | 28.7M | 29.2M | 24.3M | 40M | |||||
Imputed Operating Lease Interest Expense | 6.07M | 3.53M | 2.79M | 2.32M | 4.02M | |||||
Imputed Operating Lease Depreciation | 23.33M | 25.17M | 26.41M | 21.98M | 35.98M | |||||
Stock-Based Comp., COGS (Total) | 1.8M | 2M | 2.2M | 1.1M | 1.4M | |||||
Stock-Based Comp., R&D Exp. (Total) | 1.8M | 2M | 2.2M | 1.3M | 1.9M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 8.3M | 9.3M | 10.1M | 13.3M | 15.1M | |||||
Stock-Based Comp., Other (Total) | -2.3M | 2.7M | 2.7M | 12M | 5.6M | |||||
Total Stock-Based Compensation | 9.6M | 16M | 17.2M | 27.7M | 24M |